deCODE biostructures Initiates Research Collaboration with Cubist Pharmaceuticals
News Feb 13, 2008
deCODE biostructures, Inc. announces the signing of a collaborative research agreement with Cubist Pharmaceuticals. Under the terms of the agreement, deCODE biostructures will conduct gene to structure research on multiple proprietary targets.
Specifically, deCODE will be providing Cubist with access to deCODE’s expertise in conducting high-throughput crystallography experiments in parallel with the goal of solving multiple high resolution protein-ligand structures. deCODE will also facilitate the interpretation of X-ray structure models for structure-guided drug design efforts.
Using EBX reagents, researchers have converted the C-terminal carboxylic acid of peptides into a carbon-carbon triple bond - an alkyne (in chemical jargon a "decarboxylative alkynylation"). The alkyne moiety is a very valuable functional group that can be used to further modify the peptides.READ MORE